Report on Chinese Deproteinized Calf Blood Extractives Market, 2018-2022”
report has been added to ResearchAndMarkets.com’s
The global growth of patented nervous system drugs is slowing down. The
drugs used to treat cranial nerve and cerebral circulation systems are
experiencing a market downturn. However, the market performance is quite
different in China.
In recent years, the drug demand from neurology departments of Chinese
hospitals is growing continuously with the rapid development of the
pathogenesis of common neurological diseases and clinical pharmacology.
Deproteinized Calf Blood Extractives is a big variety and also a pillar
nervous system drug in clinical applications in China.
According to research, the sales value of Deproteinized Calf Blood
Extractives exceeded CNY 1 billion in 2017. The market was dominated by
Jinzhou Ahon Pharmaceuticals Co., Ltd., Harbin Sanctity Pharmaceutical
Co., Ltd., Jilin Connell Pharmaceutical Co., Ltd., Wuhan Humanwell
Pharmaceutical Co., Ltd., etc., with CR5 reaching over 90%.
Jinzhou Ahon Pharmaceuticals Co., Ltd. captured the biggest market
share, whose market share exceeded 70% by sales value in 2017.
Injections account for over 90% of the sales value while the market
shares of gels and eye drops are less than 5% in total. The research
expects that the Chinese Deproteinized Calf Blood Extractives market
still has some growth potential from 2018 to 2022.
Key Topics Covered
1 Relevant Concepts of Deproteinized Calf Blood Extractives
2 Overview of Chinese Deproteinized Calf Blood Extractives Market,
3 Analysis on Major Deproteinized Calf Blood Extractives Manufacturers
in China, 2013-2018
4 Prospects of Chinese Deproteinized Calf Blood Extractives Market,
For more information about this report visit https://www.researchandmarkets.com/research/nfwg8z/the_chinese?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005925/en/